Pansend Life Sciences is INNOVATE’s life sciences platform.
Pansend has a dynamic management team and Pansend’s sale of BeneVir to Janssen Biotech for up to $1 billion in 2018 demonstrates its ability to develop and monetize assets. BeneVir’s proprietary T-Stealth oncolytic virus platform develops viruses used to infect and destroy cancer cells
Pansend’s portfolio companies include:
Revolutionary devices to lighten and brighten skin in the $22 billion aesthetic dermatology market
The first real-time monitoring of kidney function, which has received “breakthrough device designation” from the FDA and addresses a $7 billion market.
A leading-edge research, engineering and development firm which specializes in regulated medical devices, in vitro diagnostics & life sciences tools as well as imaging, and industrial applications
Developing novel partial and total knee replacements for the treatment of osteoarthritis of the knee